Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

FULGENT GENETICS, INC.

(FLGT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/20/2022 01/21/2022 01/24/2022 01/25/2022 01/26/2022 Date
66.81(c) 60.7(c) 60.72(c) 63.5(c) 64.15 Last
500 126 818 982 988 836 736 699 218 540 Volume
-3.51% -9.15% +0.03% +4.58% +1.02% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 933 M - -
Net income 2021 483 M - -
Net Debt 2021 - - -
P/E ratio 2021 4,07x
Yield 2021 -
Sales 2022 601 M - -
Net income 2022 204 M - -
Net Debt 2022 - - -
P/E ratio 2022 9,91x
Yield 2022 -
Capitalization 1 894 M 1 894 M -
Capi. / Sales 2021 2,03x
Capi. / Sales 2022 3,15x
Nbr of Employees 480
Free-Float 66,9%
More Financials
Company
Fulgent Genetics, Inc. is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. The Company's... 
More about the company
Ratings of Fulgent Genetics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about FULGENT GENETICS, INC.
01/25Oppenheimer Adjusts Fulgent Genetics' Price Target to $125 From $141, Maintains Outperf..
MT
2021HelioLiver™, an Innovative Liquid Biopsy Test for the Early Detection of Liver Ca..
BU
2021Health Care Stocks Trailing Thursday Field Higher
MT
2021Health Care Stocks Higher But Log Lowest Gains Among Sectors
MT
2021Fulgent Genetics' RT-PCR COVID-19 Test Detects Omicron Variant
MT
2021Fulgent Genetics Confirms Ability to Detect Omicron Variant with RT-PCR Tests for COVID..
BU
2021FULGENT GENETICS, INC. Management's Discussion and Analysis of Financial Condition and..
AQ
2021Fulgent Genetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months E..
CI
2021Fulgent Genetics Reports Third Quarter Financial Results - Form 8-K
PU
2021Fulgent Genetics Seeks M&A
CI
2021Fulgent Genetics Reports Higher Q3 Non-GAAP EPS as Revenue More Than Doubles, Lifts 202..
MT
2021FULGENT GENETICS, INC. : Results of Operations and Financial Condition, Regulation FD Disc..
AQ
2021Fulgent Genetics Reports Third Quarter Financial Results
BU
2021Earnings Flash (FLGT) FULGENT GENETICS Reports Q3 Revenue $227.9M, vs. Street Est of $2..
MT
2021Earnings Flash (FLGT) FULGENT GENETICS Reports Q3 EPS $4.05, vs. Street Est of $3.25
MT
More news
News in other languages on FULGENT GENETICS, INC.
2021Les actions du secteur de la santé en hausse jeudi
2021Les actions du secteur de la santé sont en hausse mais enregistrent les plus faibles ga..
2021Le test RT-PCR COVID-19 de Fulgent Genetics détecte le variant Omicron
2021Fulgent Genetics annonce une hausse du bénéfice par action non GAAP au troisième trimes..
2021Earnings Flash (FLGT) FULGENT GENETICS annonce un chiffre d'affaires de 227,9 millions ..
More news
Analyst Recommendations on FULGENT GENETICS, INC.
More recommendations
Chart FULGENT GENETICS, INC.
Duration : Period :
Fulgent Genetics, Inc. Technical Analysis Chart | FLGT | US3596641098 | MarketScreener
Technical analysis trends FULGENT GENETICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 63,50 $
Average target price 125,00 $
Spread / Average Target 96,9%
EPS Revisions
Managers and Directors
Ming Hsieh Chairman, President & Chief Executive Officer
Paul H. Kim Chief Financial Officer
Han Lin Gao Chief Scientific Officer & Laboratory Director
Lawrence M. Weiss Chief Medical Officer
James Xie Chief Operating Officer
Sector and Competitors